Source comparison
BPC-157 vs TB-500 vs Combination Protocols: Comparative Analysis
BPC-157 VEGF upregulation → angiogenesis in hypovascular tissue 250–500 mcg subcutaneously daily, 4–6 weeks 10–14 days (pain reduction) Rodent models only; no human RCTs Best for vascular-limited healing; addresses the "why isn't this healing" problem in chron
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation → angiogenesis in hypovascular tissue
- 250–500 mcg subcutaneously daily, 4–6 weeks
- 10–14 days (pain reduction)
- Rodent models only; no human RCTs
- Best for vascular-limited healing; addresses the "why isn't this healing" problem in chronic cases
- TB-500
- Actin-binding → cell migration & collagen remodeling
- 2–2.5 mg subcutaneously twice weekly, 4–6 weeks
- 3–4 weeks (structural improvement)
- Wound healing trials; tendon data extrapolated
- Best for structural reorganization; targets long-term durability over symptom suppression
- BPC-157 + TB-500 stack
- Sequential pathway activation (vascular → structural)
- Both compounds at standard doses, staggered timing
- Variable (10 days to 4 weeks)
- Anecdotal only; no controlled data
- Theoretically complementary; no data on additive vs redundant effects
- Platelet-Rich Plasma (PRP)
- Growth factor cocktail → broad tissue response
- Single or serial injections, 3–6 month intervals
- 6–12 weeks
- Multiple human RCTs; moderate efficacy vs placebo
- FDA-cleared procedure; more evidence but less mechanistic precision than peptides
- The combination protocol represents the most common approach in athletic recovery communities. BPC-157 for rapid vascular recovery, TB-500 for sustained collagen remodeling. The biological rationale holds: angiogenesis precedes effective fibroblast activity, so stacking them targets sequential bottlenecks in the healing cascade. What we lack is controlled data showing whether the combination outperforms either peptide alone, or whether diminishing returns set in after the vascular phase resolves.